Challenging Global Alzheimer's Study Involving Home Infusions Exceeds Expectations

Charactered by the progressive decline in cognitive function and the ability to perform activities of daily living, Alzheimer’s Disease is an age-related neurodegenerative disorder that ultimately results in dementia with fatal complications. Evidence suggests that the pathophysiological process of Alzheimer’s begins well over a decade before the clinical stage—now recognized as Alzheimer’s dementia—and that neurodegeneration is already apparent by the stage of mild cognitive impairment.

During the COVID-19 pandemic, the delivery of elective health services for those suffering from Alzheimer’s Disease, such as hour-long intravenous infusions, were negatively impacted as it became difficult for patients to travel for treatment. During this time, one clinical team looking to retain some of its patients implemented decentralized clinical trial methods including mobile research nurses to execute home visits.

The Phase 3 clinical trial took place during the double-blind treatment period with the option for an additional 4 years during the open-label treatment period. Gain insight from the results of the trial, which focused on pre-clinical Alzheimer’s Disease where adult patients received one-hour intravenous infusions every month for 4.5 years.